Готові списки джерел за темами / Recurrent implantation failure / Статті в журналах

Статті в журналах з теми "Recurrent implantation failure"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Recurrent implantation failure.
Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 28 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Recurrent implantation failure".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Rinehart, John. "Recurrent implantation failure: definition." Journal of Assisted Reproduction and Genetics 24, no. 7 (August 3, 2007): 284–87. http://dx.doi.org/10.1007/s10815-007-9147-4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Hill, Micah J. "Recurrent implantation failure: Sapere aude." Fertility and Sterility 116, no. 6 (December 2021): 1430–31. http://dx.doi.org/10.1016/j.fertnstert.2021.09.030.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Onalan, Gogsen, and Hulusi Zeyneloglu. "Remedies for Recurrent Implantation Failure." Seminars in Reproductive Medicine 32, no. 04 (June 11, 2014): 297–305. http://dx.doi.org/10.1055/s-0034-1375182.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Wilton, L. "PGD for recurrent implantation failure." Reproductive BioMedicine Online 16 (January 2008): s7. http://dx.doi.org/10.1016/s1472-6483(10)61317-x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Vaughan, D. A., C. Harrity, K. Marron, and D. Walsh. "Thomboelastography and recurrent implantation failure." Fertility and Sterility 100, no. 3 (September 2013): S294. http://dx.doi.org/10.1016/j.fertnstert.2013.07.1039.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Garcia Velasco, J., and T. C. Li. "SESSION 22: RECURRENT IMPLANTATION FAILURE." Human Reproduction 27, suppl 2 (January 1, 2012): ii35. http://dx.doi.org/10.1093/humrep/27.s2.22.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Coughlan, C., W. Ledger, Q. Wang, Fenghua Liu, Aygul Demirol, Timur Gurgan, R. Cutting, K. Ong, H. Sallam, and T. C. Li. "Recurrent implantation failure: definition and management." Reproductive BioMedicine Online 28, no. 1 (January 2014): 14–38. http://dx.doi.org/10.1016/j.rbmo.2013.08.011.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Pacey, AllanA, Carol Coughlan, Helen Clarke, Rachel Cutting, Jane Saxton, Sarah Waite, William Ledger, and Tinchiu Li. "Sperm DNA fragmentation, recurrent implantation failure and recurrent miscarriage." Asian Journal of Andrology 17, no. 4 (2015): 681. http://dx.doi.org/10.4103/1008-682x.144946.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kusumi, Maki, Takako Kurosawa, Toshihiro Fujiwara, and Osamu Tsutsumi. "Delayed implantation may be a cause of recurrent implantation failure." IVF Lite 3, no. 2 (2016): 58. http://dx.doi.org/10.4103/2348-2907.192289.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Pirtea, Paul, Richard Thomas Scott, Dominique de Ziegler, and Jean Marc Ayoubi. "Recurrent implantation failure: how common is it?" Current Opinion in Obstetrics & Gynecology 33, no. 3 (April 12, 2021): 207–12. http://dx.doi.org/10.1097/gco.0000000000000698.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
11

Macklon, Nick S. "The true incidence of recurrent implantation failure." Current Opinion in Obstetrics & Gynecology 34, no. 3 (June 2022): 147–50. http://dx.doi.org/10.1097/gco.0000000000000781.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
12

Engin-Ustun, Yaprak, A. Ozgu-Erdinc, Emel Kiyak Caglayan, Cavidan Gulerman, Esma Sarikaya, Ayla Aktulay, Canan Demirtas, Salim Erkaya, and Nafiye Yilmaz. "Sirtuin 1 Levels in Recurrent Implantation Failure." Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics 39, no. 10 (September 1, 2017): 541–44. http://dx.doi.org/10.1055/s-0037-1606349.

Повний текст джерела
Анотація:
AbstractSirtuin 1 has an important role in cellular processes, including apoptosis and cellular stress. The purpose of this study was to assess serum sirtuin 1 levels in women with recurrent implantation failure (RIF). In this cross-sectional study, we included 28 women with RIF, 29 healthy women who had conceived by in vitro fertilization (IVF), and 30 women with a 1-cycle failure of IVF as controls. Human serum nicotinamide adenine dinucleotide (NAD)-dependent deacetylase sirtuin-1 (SIRT1/SIRT2L1) levels were detected using a commercial colorimetric kit. Recurrent implantation failure patients have higher sirtuin 1 levels than non-pregnant women and healthy pregnant women, but this difference did not reach statistical significance due to the low number of patients in our study. These higher sirtuin 1 levels may result from the inflammation imbalance of RIF patients. The only statistically significant correlation found was between age and sirtuin (r = 0.277, p = 0.009).
Стилі APA, Harvard, Vancouver, ISO та ін.
13

Li, T. C. "Response: The definition of ‘recurrent implantation failure’." Reproductive BioMedicine Online 29, no. 1 (July 2014): 146. http://dx.doi.org/10.1016/j.rbmo.2014.03.004.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
14

Das, Mausumi, and Hananel E. G. Holzer. "Recurrent implantation failure: gamete and embryo factors." Fertility and Sterility 97, no. 5 (May 2012): 1021–27. http://dx.doi.org/10.1016/j.fertnstert.2012.02.029.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
15

Günther, Veronika, Sören v. Otte, Damaris Freytag, Nicolai Maass, and Ibrahim Alkatout. "Recurrent implantation failure – an overview of current research." Gynecological Endocrinology 37, no. 7 (January 29, 2021): 584–90. http://dx.doi.org/10.1080/09513590.2021.1878136.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
16

Khalife, Dalia, and Ghina Ghazeeri. "Recurrent Implantation Failure and Low Molecular Weight Heparin." Open Journal of Obstetrics and Gynecology 08, no. 02 (2018): 146–62. http://dx.doi.org/10.4236/ojog.2018.82018.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
17

Polyakov, Alex, Wan-Tinn Teh, and Genia Rozen. "Recurrent implantation failure—It’s time to get personal." Fertility and Sterility 116, no. 5 (November 2021): 1328–29. http://dx.doi.org/10.1016/j.fertnstert.2021.08.031.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
18

Mrozikiewicz, Aleksandra E., Marcin Ożarowski, and Piotr Jędrzejczak. "Biomolecular Markers of Recurrent Implantation Failure—A Review." International Journal of Molecular Sciences 22, no. 18 (September 18, 2021): 10082. http://dx.doi.org/10.3390/ijms221810082.

Повний текст джерела
Анотація:
Currently, infertility affects 8–12% of reproductive age couples worldwide, a problem that also affects women suffering from recurrent implantation failure (RIF). RIF is a complex condition resulting from many physiological and molecular mechanisms involving dynamic endometrium–blastocyst interaction. The most important are the endometrial receptivity process, decidualization, trophoblast invasion, and blastocyst nesting. Although the exact multifactorial pathogenesis of RIF remains unclear, many studies have suggested the association between hormone level imbalance, disturbances of angiogenic and immunomodulatory factors, certain genetic polymorphisms, and occurrence of RIF. These studies were performed in quite small groups. Additionally, the results are inconsistent between ethnicities. The present review briefly summarizes the importance of factors involved in RIF development that could also serve as diagnostic determinants. Moreover, our review could constitute part of a new platform for discovery of novel diagnostic and therapeutic solutions for RIF.
Стилі APA, Harvard, Vancouver, ISO та ін.
19

Zhang, Ai-Jun, Feng Guo, and Ming-Juan Zhou. "Advances in the treatment of recurrent implantation failure." Reproductive and Developmental Medicine 1, no. 2 (2017): 123. http://dx.doi.org/10.4103/2096-2924.216860.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
20

Moustafa, Sarah, and Steven Young. "Diagnostic and therapeutic options in recurrent implantation failure." F1000Research 9 (March 25, 2020): 208. http://dx.doi.org/10.12688/f1000research.22403.1.

Повний текст джерела
Анотація:
Recurrent implantation failure (RIF) is an uncommon, imprecisely defined clinical disorder characterized by failure to achieve pregnancy after repeated embryo transfers. The diverse etiologies and incomplete understanding of RIF provide significant diagnostic and therapeutic challenges to patients and providers. Careful clinical evaluation prior to assisted reproduction can uncover many treatable causes, including thyroid dysfunction, submucosal myomas, and tobacco use. The more-subtle causes often require a more-targeted assessment. Undetected, small polyps or small areas of intrauterine synechiae are relatively common and easily treated contributors to RIF. Molecular and cellular abnormalities pose a greater therapeutic challenge. Putative causes of RIF, including progesterone resistance, shifted window of receptivity, decreased integrin expression, and immunologic disturbances, should be considered in the evaluation of a patient with otherwise unexplained RIF. It may also be true that a more complex and standardized definition of RIF would be helpful in these cases. In this paper, we review the diagnostic and therapeutic approaches to RIF, with emphasis on disorders of endometrial receptivity.
Стилі APA, Harvard, Vancouver, ISO та ін.
21

Nelson, Scott M. "Is placental haemostasis relevant to recurrent implantation failure?" Thrombosis Research 127 (February 2011): S93—S95. http://dx.doi.org/10.1016/s0049-3848(11)70025-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
22

Karaer, Abdullah, Gorkem Tuncay, Onur Uysal, Tuğba Semerci Sevimli, Nurhan Sahin, Umran Karabulut, and Ayla Eker Sariboyaci. "The role of prokineticins in recurrent implantation failure." Journal of Gynecology Obstetrics and Human Reproduction 49, no. 9 (November 2020): 101835. http://dx.doi.org/10.1016/j.jogoh.2020.101835.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
23

Sauer, R., R. Roussev, R. S. Jeyendran, J. Stern, and C. B. Coulam. "Antiphospholipid antibodies are associated with recurrent implantation failure." Fertility and Sterility 92, no. 3 (September 2009): S115. http://dx.doi.org/10.1016/j.fertnstert.2009.07.1115.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
24

Coulam, C., M. Bilal, K. Beaman, and S. Dambaeva. "DECIDUALIZATION SCORE IDENTIFIES CAUSES OF RECURRENT IMPLANTATION FAILURE." Fertility and Sterility 113, no. 4 (April 2020): e14. http://dx.doi.org/10.1016/j.fertnstert.2020.02.036.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
25

Sola-Leyva, Alberto, Inmaculada Pérez-Prieto, Laura Terrón-Camero, Nerea M. Molina, José Antonio Castilla, Juan Fontes, Luis Martinez, et al. "FUNCTIONALLY ACTIVE MICROBIOTA LANDSCAPE IN RECURRENT IMPLANTATION FAILURE." Fertility and Sterility 118, no. 4 (October 2022): e344. http://dx.doi.org/10.1016/j.fertnstert.2022.09.141.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
26

Seshadri, Srividya, and Sesh Kamal Sunkara. "Low-molecular-weight-heparin in recurrent implantation failure." Fertility and Sterility 95, no. 7 (June 2011): e29. http://dx.doi.org/10.1016/j.fertnstert.2011.03.025.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
27

Esmaeilzadeh, Sedighe, Akbar Mohammadi, Neda Mahdinejad, Faezeh Ghofrani, and Mohammad Ghasemzadeh‐Hasankolaei. "Receptivity markers in endometrial mesenchymal stem cells of recurrent implantation failure and non‐ recurrent implantation failure women: A pilot study." Journal of Obstetrics and Gynaecology Research 46, no. 8 (June 2, 2020): 1393–402. http://dx.doi.org/10.1111/jog.14340.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
28

Bahgat, Nagwan Ahmed, and Waleed Said. "Personalized embryo transfer after endometrial receptivity array test in patients with recurrent unexplained implantation failure." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 11, no. 3 (February 25, 2022): 657. http://dx.doi.org/10.18203/2320-1770.ijrcog20220380.

Повний текст джерела
Анотація:
Background: Unexplained recurrent implantation failure is a devastating situation for both patients and the doctor treating them, with transfer of high grade euploid embryos this situation became more related to the endometrial receptivity and the interaction between the embryo and the endometrium. Till now the best way of detecting endometrial receptivity was through endometrial receptivity array of gene in endometrial tissue.Methods: A retrospective study was carried out in large IVF center in Abu Dhabi in period from 2017-2021. Patients included in the study were infertile patients with age limit of 43 years old with history of repeated IVF failure after multiple transfer trials of high grade embryos. All patients had ERA test then frozen embryo transfer of Euploid high grade embryos obtained through stimulated cycle of each patient according to Era test results.Results: 45 patients included in our study. Patients divided into 2 major groups according to Era test result. First group included patients with receptive endometrium. The second group was the patients with displaced window of implantation. Patients with receptive endometrium were 12 (26.7%) and the displaced window of implantation was found in 33 patients (73.3%). Higher pregnancy and cumulative pregnancy rate in the patients with displaced window of implantation more than the receptive group 19 (57.7%) versus 5 (41.6%) and 27 (81,8%) versus 6 (50%), but lower implantation rate in the displaced window of implantation group 6/12 (50%) versus 25/53 (47.2%) with higher miscarriage rate in the receptive group 2/6 (33.3%) versus 4/26 (14.8%), live birth and take home baby rate in the patients with displaced window of implantation 3 babies delivered to the receptive group 3/12 (25%), 24 babies to the group of displaced window of implantation 24/53 (45.3%).Conclusions: Patients with recurrent unexplained implantation failure may benefit from personalized embryo transfer after determining their window of implantations with endometrial receptivity array testing.
Стилі APA, Harvard, Vancouver, ISO та ін.
29

BOLEAC, Ioan, Manuela NEAGU, Anca CORICOVAC, Dorina CODREANU, Alina BUSAN-PIRVOIU, and Bogdan MARINESCU. "Clinical applications of endometrial receptivity tests in patients with recurrent implantation failure." Romanian Journal of Medical Practice 16, no. 1 (March 31, 2021): 79–85. http://dx.doi.org/10.37897/rjmp.2021.1.14.

Повний текст джерела
Анотація:
Recurrent implantation failure is represented by the failure to achieve a clinical pregnancy after transfer of at least 4 good-quality embryos in a minimum of 3 fresh or frozen cycles in a woman under the age of 40 years. One of the recent approaches in studying the window of implantation was building the expression profile of the genes of the endometrial cells. We performed a retrospective study which investigated if endometrial receptivity tests improved the outcomes of IVF procedures in patients with recurrent implantation failure. We enrolled 47 couples with RIF and divided them in 2 groups: the first group of 22 couples performed the ERA test and the embryo transfer according to the result of the test; the second group of 27 couples had the embryo transfer done without the ERA test. Our conclusion was that the ERA test did not improve the outcomes for patients with recurrent implantation failure.
Стилі APA, Harvard, Vancouver, ISO та ін.
30

Sebastian-Leon, P., N. Garrido, J. Remohí, A. Pellicer, and P. Diaz-Gimeno. "Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure†." Human Reproduction 33, no. 4 (February 14, 2018): 626–35. http://dx.doi.org/10.1093/humrep/dey023.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
31

Assaad, Mahmoud, Sinan Sarsam, Amir Naqvi, and Marcel Zughaib. "CardioMems® device implantation reduces repeat hospitalizations in heart failure patients: A single center experience." JRSM Cardiovascular Disease 8 (January 2019): 204800401983329. http://dx.doi.org/10.1177/2048004019833290.

Повний текст джерела
Анотація:
Introduction Hospital readmission for congestive heart failure remains one of the most important economic burdens on healthcare cost. The implantation of a wireless pressure monitoring device (CardioMEMS®) had led to nearly 40% reduction in readmission rates in the landmark CHAMPION trial. We aim to study the effectiveness of this wireless device in reducing heart failure admissions in a real-world setting. Methods This is a retrospective chart review of patients with recurrent admissions for heart failure implanted with the wireless pressure monitoring system (CardioMEMS®) at our institution. We studied the total number of all-cause hospital admissions as well as heart failure-related admissions pre- and post-implantation. Results A total of 27 patients were followed for 6–18 months. The total number of all-cause hospital admissions prior to device implantation was 61 admissions for all study patients, while the total number for the post-implantation period was 19, correlating with 2.26 + 1.06 admissions/person-year prior to device implantation versus 0.70 + 0.95 admissions/person-year post-implantation (p-value < 0.001). For heart failure-related admissions, the total number prior to device implantation was 46 compared to 9 admissions post device implantations, correlating with 1.70 + 1.07 admissions/person-years pre-implantation versus 0.33 + 0.62 admissions/person-years post-implantation (p-value < 0.001). This translates to 80.4% and 68.9% reduction in heart failure and all-cause admissions, respectively. Conclusion In a real-world setting, the implantation of a wireless heart failure monitoring system in patients with heart failure and class III symptoms has resulted in 80.4% reduction in heart failure admissions and 69% reduction in all-cause admissions.
Стилі APA, Harvard, Vancouver, ISO та ін.
32

Liu, Su, Hongxia Wei, Yuye Li, Chunyu Huang, Ruochun Lian, Jian Xu, Lanna Chen, and Yong Zeng. "Downregulation of ILT4+dendritic cells in recurrent miscarriage and recurrent implantation failure." American Journal of Reproductive Immunology 80, no. 4 (June 14, 2018): e12998. http://dx.doi.org/10.1111/aji.12998.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
33

Kurdoğlu, Mertihan. "Recurrent Implantation Failure: Is It Time to Redefine It?" Crescent Journal of Medical and Biological Sciences 9, no. 3 (July 29, 2022): 130–31. http://dx.doi.org/10.34172/cjmb.2022.22.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
34

Turocy, Jenna, and Zev Williams. "Novel therapeutic options for treatment of recurrent implantation failure." Fertility and Sterility 116, no. 6 (December 2021): 1449–54. http://dx.doi.org/10.1016/j.fertnstert.2021.10.025.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
35

Franasiak, Jason M., Diana Alecsandru, Eric J. Forman, Laura C. Gemmell, Jeffrey M. Goldberg, Natalia Llarena, Cheri Margolis, Joop Laven, Sam Schoenmakers, and Emre Seli. "A review of the pathophysiology of recurrent implantation failure." Fertility and Sterility 116, no. 6 (December 2021): 1436–48. http://dx.doi.org/10.1016/j.fertnstert.2021.09.014.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
36

Samadhiya, Richa, GirrajPrasad Swarnkar, Arti Singh, and PriyaBhave Chittawar. "Role of endometrial receptivity array in recurrent implantation failure." Fertility Science and Research 8, no. 2 (2021): 180. http://dx.doi.org/10.4103/fsr.fsr_40_21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
37

Coughlan, C., X. Yuan, T. Nafee, J. Yan, N. Mariee, and TC Li. "The clinical characteristics of women with recurrent implantation failure." Journal of Obstetrics and Gynaecology 33, no. 5 (July 2013): 494–98. http://dx.doi.org/10.3109/01443615.2013.782280.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
38

Cakiroglu, Yigit, and Bulent Tiras. "Determining diagnostic criteria and cause of recurrent implantation failure." Current Opinion in Obstetrics and Gynecology 32, no. 3 (June 2020): 198–204. http://dx.doi.org/10.1097/gco.0000000000000620.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
39

Quenby, Siobhan, and Roy Farquharson. "Uterine natural killer cells, implantation failure and recurrent miscarriage." Reproductive BioMedicine Online 13, no. 1 (January 2006): 24–28. http://dx.doi.org/10.1016/s1472-6483(10)62012-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
40

Zorina, IV, and SA Yakovenko. "Evaluation and treatment of patients with recurrent implantation failure." Reproductive BioMedicine Online 17 (September 2008): S—19. http://dx.doi.org/10.1016/s1472-6483(11)60645-7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
41

Vlachadis, Nikolaos, Nikolaos Vrachnis, Emmanouel Economou, and Charalambos Siristatidis. "Zooming in on the definition of ‘recurrent implantation failure’." Reproductive BioMedicine Online 29, no. 1 (July 2014): 144–45. http://dx.doi.org/10.1016/j.rbmo.2014.03.003.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
42

Wilczyńska, K., A. Wiśniewski, R. Krasiński, P. Radwan, M. Radwan, J. R. Wilczyński, A. Malinowski, P. Kuśnierczyk, and I. Nowak. "Recurrent implantation failure and soluble HLA-G plasma levels." Journal of Reproductive Immunology 122 (August 2017): 46–47. http://dx.doi.org/10.1016/j.jri.2017.07.028.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
43

Demiral, I., E. Bastu, T. Gunel, U. Sezerman, E. Gumusoglu, E. Ulgen, M. K. Hosseini, F. Buyru, and J. Yeh. "Endometrial gene expression in patients with recurrent implantation failure." Fertility and Sterility 108, no. 3 (September 2017): e365. http://dx.doi.org/10.1016/j.fertnstert.2017.07.1068.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
44

Elsaid, Samir, Tarek Toppozada, Eman Ali, and Fahd Mansour. "CHRONIC ENDOMETRITIS IN CASES WITH RECURRENT EMBRYO IMPLANTATION FAILURE." ALEXMED ePosters 4, no. 4 (December 1, 2022): 14–15. http://dx.doi.org/10.21608/alexpo.2022.170587.1494.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
45

Huang, Jin, Hao Qin, Yihua Yang, Xiaoyan Chen, Jiamiao Zhang, Susan Laird, Chi Chiu Wang, Ting Fung Chan, and Tin Chiu Li. "A comparison of transcriptomic profiles in endometrium during window of implantation between women with unexplained recurrent implantation failure and recurrent miscarriage." Reproduction 153, no. 6 (June 2017): 749–58. http://dx.doi.org/10.1530/rep-16-0574.

Повний текст джерела
Анотація:
The endometrium becomes receptive to the embryo only in the mid-luteal phase, but not in the other stages of the menstrual cycle. Endometrial factors play an important role in implantation. Women with recurrent miscarriage and recurrent implantation failure have both been reported to have altered expression of receptivity markers during the window of implantation. We aimed to compare the gene expression profiles of the endometrium in the window of implantation among women with unexplained recurrent implantation failures (RIF) and unexplained recurrent miscarriages (RM) by RNA sequencing (RNA-Seq). In total 20 patients (9 RIF and 11 RM) were recruited. In addition 4 fertile subjects were included as reference. Endometrium samples were precisely timed on the 7th day after luteal hormone surge (LH + 7). All the 24 endometrium samples were extracted for total RNA. The transcriptome was determined by RNA-Seq in the first 14 RNA samples (5 RIF, 6 RM and 3 fertile). Differentially expressed genes between RM and RIF were validated by quantitative real-time PCR (qPCR) in all 24 RNA samples (9 RIF, 11 RM and 4 fertile). Transcriptomic profiles of RM and RIF, but not control samples, were separated from each other by principle component analysis (PCA) and support vector machine (SVM). Complementary and coagulation cascades pathway was significantly up-regulated in RIF while down-regulated in RM. Differentially expressed genes C3, C4, C4BP, DAF, DF and SERPING1 in complement and coagulation cascade pathway between RM and RIF were further validated by qPCR. This study compared endometrial transcriptome among patients with RIF and RM in the window of implantation; it identified differential molecular pathways in endometrium between RIF and RM, which potentially affect the implantation process.
Стилі APA, Harvard, Vancouver, ISO та ін.
46

Benkhalifa, Mustapha, Fabien Joao, Cynthia Duval, Debbie Montjean, Molka Bouricha, Rosalie Cabry, Marie-Claire Bélanger, Hatem Bahri, Pierre Miron, and Moncef Benkhalifa. "Endometrium Immunomodulation to Prevent Recurrent Implantation Failure in Assisted Reproductive Technology." International Journal of Molecular Sciences 23, no. 21 (October 24, 2022): 12787. http://dx.doi.org/10.3390/ijms232112787.

Повний текст джерела
Анотація:
After more than four decades of assisted reproductive technology (ART) practice worldwide, today more than 60% of women undergoing in vitro fertilization (IVF) treatments fail to become pregnant after the first embryo transfer and nearly 20% of patients are suffering from unexplained recurrent implantation failures (RIFs) and repeated pregnancy loss (RPL). The literature reported different causes of RIF–RPL, mainly multifactorial, endometrial and idiopathic. RIF remains a black box because of the complicated categorization and causes of this physio-pathological dysregulation of implantation and pregnancy process after ovarian stimulation. Many options were suggested as solutions to treat RIF–RPL with controversial results on their usefulness. In this article, we reviewed different possible therapeutic options to improve implantation rates and clinical outcomes. Based on our experience we believe that endometrium immunomodulation after intrauterine insemination of activated autologous peripheral blood mononuclear cells (PBMCs) or platelet-rich plasma (PRP) can be a promising therapeutic solution. On the other hand, peripheral lymphocyte balance typing, specific cytokines and interleukins profiling can be proposed as predictive biomarkers of implantation before embryo transfer.
Стилі APA, Harvard, Vancouver, ISO та ін.
47

Al-Lamee, Hannan, Amy Ellison, Josephine Drury, Christopher J. Hill, Andrew J. Drakeley, Dharani K. Hapangama, and Nicola Tempest. "Altered endometrial oestrogen-responsiveness and recurrent reproductive failure." Reproduction and Fertility 3, no. 1 (March 1, 2022): 30–38. http://dx.doi.org/10.1530/raf-21-0093.

Повний текст джерела
Анотація:
Graphical abstract Abstract Recurrent reproductive failure (RRF) encompasses recurrent implantation failure (RIF) and recurrent pregnancy loss (RPL). These highly prevalent, distressing conditions have many unanswered questions regarding aetiology and management. Oestrogen receptor beta (ERβ) is the predominant oestrogen receptor expressed in the vascular endothelium of the endometrium during the window of implantation (WOI). The establishment of normal endometrial receptivity is integrally associated with progesterone receptor (PR). Therefore, we aimed to investigate whether women with RRF have clinical, type-specific endometrial aberrations of ERβ, PR and Ki-67 expression during the WOI. Thirty-eight endometrial biopsies were collected; 29 RRF (10 RIF, 9 recurrent loss of early pregnancy (RLEP) and 10 recurrent fetal loss (RFL)) and 9 fertile controls (FC). Within RIF, RLEP and RFL groups, the perivascular compartment showed significantly lower levels of ERβ vs FC (P = 0.02, P = 0.03 and P = 0.01, respectively). Vascular endothelium also displayed significantly lower levels of ERβ within RIF and RFL cohorts vs FC (P = 0.03 and P = 0.003). The expression of Ki-67 was significantly lower within vascular endothelium of all RRF; RIF (P = 0.02), RLEP (P = 0.02) and RFL (P <0.01). PR was significantly reduced (P <0.001) in the perivascular area of women with RIF. These findings provide novel insights into biological correlates of clinical subtypes of RRF. The endometrium of women with RRF display significantly altered levels of ERβ, PR and Ki-67 during the WOI, furthering our understanding of the defective endometrial phenotype of women suffering from RRF, with possible impaired glandular function, angiogenesis and decidualisation. Lay summary Recurrent reproductive failure (RRF) refers to a group of devastating conditions with many unanswered questions regarding their causes and treatment options. The lining of the womb, the endometrium, is primed and suitable for successful embryo implantation for a short time during the menstrual cycle; the window of implantation (WOI). Oestrogen is a key hormone that plays an important role in regulating the endometrium and its effects are exerted via two oestrogen receptor subtypes. Oestrogen receptor beta (ERβ) is the main oestrogen receptor present during the WOI. Progesterone receptor allows the other main hormone, progesterone, to influence the endometrial activity and Ki-67 reflects the proliferative activity of the cells within the endometrium. We investigated the expression of these markers in endometrial samples collected from women with RRF and proven fertility. We found that the endometrium of women with RRF has significantly lower levels of ERβ and Ki-67 during the WOI, possibly leading to unsuccessful pregnancies.
Стилі APA, Harvard, Vancouver, ISO та ін.
48

Guo, Xi, Hong Yi, Tin Chiu Li, Yu Wang, Huilin Wang, and Xiaoyan Chen. "Role of Vascular Endothelial Growth Factor (VEGF) in Human Embryo Implantation: Clinical Implications." Biomolecules 11, no. 2 (February 10, 2021): 253. http://dx.doi.org/10.3390/biom11020253.

Повний текст джерела
Анотація:
Vascular endothelial growth factor (VEGF) is a well-known angiogenic factor that plays a critical role in various physiological and pathological processes. VEGF also contributes to the process of embryo implantation by enhancing embryo development, improving endometrial receptivity, and facilitating the interactions between the developing embryo and the endometrium. There is a correlation between the alteration of VEGF expression and reproductive failure, including recurrent implantation failure (RIF) and recurrent miscarriage (RM). In order to clarify the role of VEGF in embryo implantation, we reviewed recent literature concerning the expression and function of VEGF in the reproductive system around the time of embryo implantation and we provide a summary of the findings reported so far. We also explored the effects and the possible underlying mechanisms of action of VEGF in embryo implantation.
Стилі APA, Harvard, Vancouver, ISO та ін.
49

Liu, Su, Hongxia Wei, Yuye Li, Lianghui Diao, Ruochun Lian, Xu Zhang, and Yong Zeng. "Characterization of dendritic cell (DC)-10 in recurrent miscarriage and recurrent implantation failure." Reproduction 158, no. 3 (September 2019): 247–55. http://dx.doi.org/10.1530/rep-19-0172.

Повний текст джерела
Анотація:
During pregnancy, the maternal immune system must tolerate the persistence of semi-allogeneic fetus in the maternal tissue. Inadequate recognition of fetal antigens may lead to pregnancy complications, such as recurrent miscarriage (RM) and recurrent implantation failure (RIF). Dendritic cells (DCs) are key regulators of protective immune responses and the development and maintenance of tolerance. Regarding that DCs are important in the establishment of immune tolerance in human pregnancy, it would be important to study the microenvironment in which DCs reside or are activated may affect their functions toward tolerance rather than active immune response. IL-10 plays a critical role in the maintenance of normal pregnancy, and the increased production of IL-10 is associated with successful pregnancy. In this study, we provide an in-depth comparison of the phenotype and cytokine production by DC-10 and other DC subsets, such as iDC and mDC. CD14+ monocyte-derived DCs were differentiated in the presence of IL-10 (DC-10) in vitro from ten normal fertile controls, six RM women and seven RIF women, and characterized for relevant markers. DC-10 was characterized by relatively low expression of costimulatory molecule CD86, as well as MHC class II molecule HLA-DR, high expression of tolerance molecules HLA-G, ILT2, ILT4 and immunosuppressive cytokine IL-10, but produced little or no proinflammatory cytokines, such as TNF-α, IL-6 and IL-12p70. Our study provides a better understanding of the phenotypical properties of DC-10, which may participate in the complex orchestration that leads to maternal immune tolerance and homeostatic environment in human pregnancy.
Стилі APA, Harvard, Vancouver, ISO та ін.
50

Mekinian, Arsène, Jonathan Cohen, Jaume Alijotas-Reig, Lionel Carbillon, Pascale Nicaise-Roland, Gilles Kayem, Emile Daraï, Olivier Fain, and Marie Bornes. "Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?" American Journal of Reproductive Immunology 76, no. 1 (February 5, 2016): 8–28. http://dx.doi.org/10.1111/aji.12493.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії